Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 24.
Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE:SGP)
today reported two data presentations supporting response guided
therapy with boceprevir combination therapy in patients with
chronic hepatitis C virus (HCV) genotype 1....
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Court Rejects Drug-Patent ChallengeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Supreme Court Monday rejected a generic-drug maker's appeal challenging a patent for a blood-thinning drug developed by Sanofi-Aventis.
Source: WSJ.com: Health - November 2, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Genomics: No Longer A FailureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Mapping the human genome produced far more hype than drugs. That's starting to change.
Source: Forbes.com Healthcare News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Ingen CEO Live Radio Interview Tomorrow With The Money ChannelEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
YUCAIPA, Calif., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.
Source: Medical News (via PRIMEZONE) - November 2, 2009 Category: Pharmaceuticals Source Type: news
02.11.09: Successful purchase of trait platform with extensive product pipeline:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience completes acquisition of biotech company Athenix Corp.Purchase price of USD 365 million plus milestonesmehr ...
Source: Bayer IR Newsfeed: Events - November 2, 2009 Category: Pharmaceuticals Source Type: news
Insurance, Pet Care, Pharmaceuticals, and Law Enforcement Industries All Find KismetEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Kismet Talent Agency is Named Exclusive Sales Agent for Prominent Domain Names in the Insurance and Bonding, Pet Care, Drug and Pharmaceutical, and Law Enforcement Industries. (PRWeb Nov 2, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb2718014.htm
Source: PRWeb: Medical Pharmaceuticals - November 2, 2009 Category: Pharmaceuticals Source Type: news
AtCor Medical Holdings Ltd.: New Cardiovascular Risk Factor IdentifiedEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ITASCA, IL (MARKET WIRE) AtCor Medical (ASX: ACG) the developer and marketer of the SphygmoCor(R) system which measures central blood pressure and arterial stiffness noninvasively, today announced the publication of a key National Institutes of Health (NIH)-funded study(1) using SphygmoCor in the Journal of the American College of Cardiology (JACC).
Source: Market Wire - Pharmaceuticals and Biotech - November 2, 2009 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare ACG Source Type: news
Cequent closes tranche of $10.8M roundEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cambridge-based biotechnology company Cequent Pharmaceuticals has raised $2.7 million of a planned $10.8 million financing round. The funding included investments from Wellesley, Mass.-based Ampersand Ventures, New England Capital Partners in Newton, Mass., and Durham, N.C.-based A.M. Pappas Life Science Ventures.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2009 Category: Pharmaceuticals Source Type: journals
Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent SystemEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Third-generation drug-eluting stent now available in CE Mark countries
NATICK, Mass., Nov. 2 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today announced it has received CE Mark for its PROMUS® Element(TM) Everolimus-Eluting Coron... Devices, Interventional Cardiology, RegulatoryBoston Scientific, PROMUS Element, drug eluting stent
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
AGA Medical Wins Injunction Against Occlutech's Figulla FlexEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MINNEAPOLIS, Nov., 2--(HSMN NewsFeed)--AGA Medical Holdings, Inc. (AGA Medical) (NASDAQ:AGAM ) today announced that the German Regional Court in Düsseldorf, Germany has granted a preliminary injunction against the manufacture, possession and sale of t... Devices, InterventionalAGA Medical, Occlutech, Figulla Flex
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
Bayer CropScience completes acquisition of biotech company Athenix Corp.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Purchase price of USD 365 million plus milestones
Source: Bayer Company News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Merit Medical to Present at Canaccord Adams' Cardiovascular ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOUTH JORDAN, Utah, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and gastroenterology, today announced that it will participate at Canaccord Adams' Third Annual Cardiovascular Conference being held November 10th, 2009 at the Nikko Hotel in San Francisco.
Source: Medical News (via PRIMEZONE) - November 2, 2009 Category: Pharmaceuticals Source Type: news
KCI Announces Final Approval to Enter Japan MarketEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Formal regulatory approval enables commercialization of innovative V.A.C.® Therapy System in Japan
SAN ANTONIO, Nov., 2--(HSMN NewsFeed)--Kinetic Concepts, Inc. (NYSE: KCI ) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Ja... Devices, Wound Care, RegulatoryKinetic Concepts, V.A.C. Therapy
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
Mednax Q3 income surges 29%Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Mednax boosted its earnings by 29 percent in the third quarter as its physicians saw more patients. (MD)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2009 Category: Pharmaceuticals Source Type: journals
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of Benlysta in Systemic Lupus ErythematosusEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- BENLYSTA (belimumab) 10 mg/kg plus standard of care met its
primary efficacy endpoint by achieving a statistically significant
improvement in patient response rate versus placebo plus standard
of care at Week 52 in BLISS-76 -
- Primary...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
SIUE, SLU get stimulus for pain studyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Southern Illinois University Edwardsville School of Pharmacy and the Saint Louis University Department of Pharmacology and Physiology have won $974,024 in stimulus money to study new ways to relieve chronic pain.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2009 Category: Pharmaceuticals Source Type: journals
Mallinckrodt painkiller gets FDA OKEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A generic painkiller developed by Covidien’s pharmaceutical subsidiary, Mallinckrodt Inc., has received approval from the U.S. Food and Drug Administration.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2009 Category: Pharmaceuticals Source Type: journals
Enzo Biochem Reports Favorable Clinical Trial Of EGS21 For Treatment Of Non-Alcoholic SteatohepatitisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Enzo Biochem Inc. (NYSE:ENZ) announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome. Enzo
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen AllergiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
KENILWORTH, N.J., Nov 02, 2009
/PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation
(NYSE: SGP) today announced that its investigational sublingual
Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met
the primary endpoint...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
QUÉBEC CITY, Nov. 2 /CNW Telbec/ - Æterna Zentaris
Inc. (TSX: AEZ; Nasdaq: AEZS) (the "Company"), a global
biopharmaceutical company focused on endocrine therapy and
oncology, today announced positive efficacy data from a Phase 2
study...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
QUÉBEC CITY, Nov. 2 /CNW Telbec/ - Æterna Zentaris
Inc. (TSX: AEZ; Nasdaq: AEZS) (the "Company"), a global
biopharmaceutical company focused on endocrine therapy and
oncology, today announced positive efficacy data from a Phase 2
study with...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced MelanomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BERKELEY HEIGHTS, NJ – October 29, 2009 - Genta
Incorporated (OTCBB: GETA) today announced top-line results from
AGENDA, the Company’s Phase 3 trial of Genasense®
(oblimersen sodium) Injection in patients with...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Human Genome Sciences sees positive results for lupus drugEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Human Genome Sciences Inc. said its second round of late-stage clinical trials proved positive for its key lupus drug, cementing the Rockville company's recent successes and boosting its chances for selling the first federally approved lupus treatment in five decades. (HGSI)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2009 Category: Pharmaceuticals Source Type: journals
GlobeImmune's Hepatitis C Therapeutic Vaccine Combined with Standard of Care Increases End of Treatment Response Rate by 15%Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Phase 2b Data Presented at American Association for the Study of
Liver Diseases Meeting
LOUISVILLE, Colo., Nov. 2, 2009 - GlobeImmune Inc. will present
Phase 2b data today at the 60th Annual Meeting of the American
Association for the Study of Liver...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve ReplacementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Company Expands Minimally Invasive Program
MINNEAPOLIS, Nov. 2 (HSMN NewsFeed) -- ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced the first human robot assisted endoscop... Devices, CardiologyATS Medical, endoscopic aortic valve replacement, Aortic Bioprosthesis, daVinci
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
Toshiba Introduces New Premium Mid-Sized Ultrasound SystemEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Aplio MX Offers Hospitals Exceptional Value with Advanced Clinical Performance and Improved Portability
TUSTIN, Calif., Nov 2--(HSMN NewsFeed)--Hospitals use ultrasound as a first-line diagnostic exam, requiring them to have cutting-edge ultrasound tech... DevicesToshiba America Medical Systems, Aplio MX, ultrasound
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus ErythematosusEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BENLYSTA (belimumab) 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo plus standard of care at Week 52 in BLISS-76
Primary efficacy endpoint met... BiopharmaceuticalsHuman Genome Sciences, GlaxoSmithKline, BENLYSTA, belimumab, lupus, BLISS-76
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R))Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
TOKYO, November 2 (HSMN NewsFeed) -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distributi... Biopharmaceuticals, DistributionSosei Group, ASKA Pharmaceuticals, SOH-075, NorLevo, morning after pill
Source: HSMN NewsFeed - November 2, 2009 Category: Pharmaceuticals Source Type: news
Novobiotics - Positive Initial Phase IIa DataEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LONDON, Nov. 2, 2009--Biotechnology company NovaBiotics, which
focuses on the design and development of novel peptide antifungal
and antibacterial therapeutics, confirms that the first patients
enrolled in its Novexatin® Phase IIa clinical trial...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
AG Mednet Announces Milestones in Electronic Image Submission Compliance and Broad Worldwide Adoption of Its Network PlatformEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BOSTON, Nov. 2, 2009 (GLOBE NEWSWIRE) -- AG Mednet, the world's largest diagnostic imaging network, announced today that more than 2000 users around the world have been credentialed to access and use its electronic diagnostic image submission platform. With users across 40 countries and in every continent, submitting de-identified diagnostic image exams and transmittal forms for over 40 clinical trials, AG Mednet is now the de facto standard for sponsors, imaging core labs, CROs and investigator sites who take advantage of the robustness of this green solution.
Source: Medical News (via PRIMEZONE) - November 2, 2009 Category: Pharmaceuticals Source Type: news
Retigabine Regulatory UpdateEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA), for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures
Source: GSK news - November 2, 2009 Category: Pharmaceuticals Source Type: organizations
Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patients treated with PegatronEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Canadian POWeR and REDIPEN(R) Programs presented at the
American Association for the Study of Liver Diseases Annual Meeting
-
KIRKLAND, QC, Nov. 2 /CNW/ - Results from two significant
Canadian studies underscore the growing scientific...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
National Competitive Bidding For Manufacturers – Surprise?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From Homecare Monday
So – surprise surprise – in the latest round of proposals there is one that orders an investigation possibly that manufacturers of homecare products are going to be asked to bid.
Of course we have been saying for some time that the traditional supply lines between manufacturers and dealers / distributors / buying organizations are blurring, not only as a result of this competitive pressure but the bar has been lowered because of the ease of Asian sourcing for manufacturers and distributors alike.
This is happening in several countries in Europe as well – come to think of it the Briti...
Source: the international medical market place - November 2, 2009 Category: Pharmaceuticals Authors: Editor Tags: Editorial Home Healthcare linkedin national competitive bidding NHS Source Type: info
Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
First HEPLISAV Chronic Kidney Disease Data to be Presented at
IDSA
BERKELEY, Calif.--(BUSINESS WIRE)--Oct 29, 2009 - Dynavax
Technologies Corporation (Nasdaq: DVAX) today announced the first
clinical data for HEPLISAVTM investigational...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Salix Pharmaceuticals Reviews American Association for the Study of Liver Diseases Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Data Demonstrate Protective Effect and Durability of
Rifaximin for Maintenance of Remission of Hepatic
Encephalopathy
Data Demonstrate Rifaximin Significantly Improved Critical
Flicker Frequency and Time-Weighted CFF Correlated with Overt
Hepatic...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Avila Presents Data on Its Novel, Orally-Available Protease Inhibitor, AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical ModelsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Potential for Rapid and Prolonged Therapeutic Benefit in HCV
through Protein Silencing of NS3 Protease
BOSTON & WALTHAM, Mass.--(BUSINESS WIRE)--Nov 2, 2009 -
Avila Therapeutics™, Inc., a biotechnology company developing
novel covalent...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated AmyloidosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
– New Data Demonstrate Durable In Vivo Efficacy for
ALN-TTR –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2009 - Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it presented new...
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials
Chelsea Therapeutics Appoints Dr. William D. Schwieterman Chief Medical OfficerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHARLOTTE, N.C, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the appointment of William D. Schwieterman, M.D., to the newly created position of Chief Medical Officer. Dr. Schwieterman, who resigned his seat on Chelsea's Board of Directors to assume the position, will be responsible for medical and regulatory affairs, and will report to Simon Pedder, Ph.D., Chelsea's President and Chief Executive Officer.
Source: Medical News (via PRIMEZONE) - November 2, 2009 Category: Pharmaceuticals Source Type: news
BioForm Medical Reports Financial Results for Quarter Ended September 30, 2009, First Quarter of Fiscal 2010Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN MATEO, Calif., Nov. 2, 2009 (GLOBE NEWSWIRE) -- BioForm Medical, Inc. (Nasdaq:BFRM) today announced its financial results for the quarter ended September 30, 2009, which is the Company's first quarter of fiscal 2010. Net sales were $18.3 million for the quarter ended September 30, 2009 as compared to $15.7 million for the quarter ended September 30, 2008, an increase of $2.6 million or 16.6 %. The net loss was approximately $0.6 million for the quarter ended September 30, 2009 as compared to a net loss of $7.8 million for the quarter ended September 30, 2008. Cash and cash equivalents increased during the quarter by $0...
Source: Medical News (via PRIMEZONE) - November 2, 2009 Category: Pharmaceuticals Source Type: news
Eriez' E-Z Tec® DSP Narrow Profile Liquid Line Metal Detectors Provide Protection From Contamination And Equipment DamageEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Eriez' E-Z Tec® DSP Narrow Profile Liquid Line Metal Detectors are used to detect the presence of ferrous, nonferrous and stainless metal contaminants in viscous products such as liquids, slurries, syrups, pastes and many other pumped materials.
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Mar Cor Purification Announces It Has Shipped It's 12,000th Portable RO For Dialysis ApplicationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Mar Cor Purification, Inc. announced that it has shipped the 12,000th portable RO used in single patient dialysis applications. The unit was sold to Fresenius Medical Care (FMC) for use in treating patients in home and acute settings.
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
BioTek Instruments And Millipore Collaborate On Application Note For Hormone Assay PanelEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BioTek Instruments, Inc., in collaboration with Millipore Corporation, has released the application note, "Automated Magnetic Bead Washing of Metabolic Hormone Assays" featuring BioTek's new ELx405™ Magnetic Bead Washer and Millipore's MILLIPLEX™ MAP Metabolic Hormone Assay Panel.
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
U.S. Food And Drug Administration (FDA) Selects Quality Management System (QMS) Software Solution From MasterControl And i4DMEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MasterControl, a global provider of software solutions that enable regulated companies to improve internal efficiency and reduce overall costs while accelerating time to market, announced recently that the company and i4DM, a MasterControl partner, have been selected as the software provider and implementation team of a quality management system (QMS) for the Food and Drug Administration (FDA).
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Lupus Drug Shows Promising ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Human Genome and GlaxoSmithKline said their experimental drug Benlysta met the goal of a second late-stage study in treating lupus, making it likely to be the first treatment in decades for the hard-to-treat autoimmune disease.
Source: WSJ.com: Health - November 2, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
FDA: Byetta Label Revised To Include Safety Information On Possible Kidney ProblemsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosusEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Benlysta (belimumab) 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo plus standard of care at Week 52 in BLISS-76
- Primary efficacy endpoint met in two pivotal Phase 3 trials, as specified by Special Protocol Assessment agreement with FDA
Source: GSK news - November 2, 2009 Category: Pharmaceuticals Source Type: organizations
BioVex Announces Publication Of Phase 2 Melanoma Results With OncoVEX (GM-CSF) In The Journal Of Clinical OncologyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO).
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news
GE Healthcare, DoveBid Expand Life Sciences Asset Disposal CapabilitiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GE Healthcare has announced a strategic collaboration with GoIndustry DoveBid to enhance its asset disposal capabilities.
Source: PharmaManufacturing.com - November 2, 2009 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: info
Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with DiabetesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Abbott.com - November 2, 2009 Category: Pharmaceuticals Source Type: organizations
